| [ Summary ] |
Given its antiresorptive efficacy as a selective estrogen receptor modulator (SERM), raloxifene (RLX) has been commonly used in the prevention and treatment of osteoporosis, in addition to administration of bisphosphonates. Recently, bazedoxifene (BZA) has also become available for clinical use. Therefore, in this review, major differences between BZA and RLX are outlined. Although differing levels of protective efficacy inpreventing non‒vertebral fractures has been highlighted, the focus is on differing levels of clinical efficacy in real‒world settings. Furthermore, given that human breast cancer cells have an approximate 20 % gene homology to normal cells, RLX and BZA are expected to differ to some extent in their effects on breast cancer cells. While SERMs are also expected to offer benefits "beyond the breast" and "beyond the bone", BZA/conjugated estrogen combination (TSEC) treatment is highlighted to illustrate these effects. |